VanDyke K - Search Results

1

Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.

Zeissig MN, Hewett DR, Mrozik KM, Panagopoulos V, Wallington-Gates CT, Spencer A, Dold SM, Engelhardt M, Vandyke K, Zannettino ACW. Zeissig MN, et al. Among authors: vandyke k. Leuk Res. 2024 Apr;139:107469. doi: 10.1016/j.leukres.2024.107469. Epub 2024 Mar 7. Leuk Res. 2024. PMID: 38479337 Free article.

2

Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.

Williams CMD, Noll JE, Bradey AL, Duggan J, Wilczek VJ, Masavuli MG, Grubor-Bauk B, Panagopoulos RA, Hewett DR, Mrozik KM, Zannettino ACW, Vandyke K, Panagopoulos V. Williams CMD, et al. Among authors: vandyke k. Br J Haematol. 2023 Nov;203(4):614-624. doi: 10.1111/bjh.19102. Epub 2023 Sep 12. Br J Haematol. 2023. PMID: 37699574 Free PMC article.

3

Mesenchymal stromal cell senescence in haematological malignancies.

Plakhova N, Panagopoulos V, Vandyke K, Zannettino ACW, Mrozik KM. Plakhova N, et al. Among authors: vandyke k. Cancer Metastasis Rev. 2023 Mar;42(1):277-296. doi: 10.1007/s10555-022-10069-9. Epub 2023 Jan 9. Cancer Metastasis Rev. 2023. PMID: 36622509 Review.

4

Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma.

Ebert LM, Vandyke K, Johan MZ, DeNichilo M, Tan LY, Myo Min KK, Weimann BM, Ebert BW, Pitson SM, Zannettino ACW, Wallington-Beddoe CT, Bonder CS. Ebert LM, et al. Among authors: vandyke k. Mol Oncol. 2022 Mar;16(6):1221-1240. doi: 10.1002/1878-0261.13055. Epub 2021 Jul 24. Mol Oncol. 2022. PMID: 34245117 Free PMC article.

5

Seed and soil revisited in multiple myeloma.

Vandyke K. Vandyke K. Blood. 2021 Apr 29;137(17):2282-2283. doi: 10.1182/blood.2020009555. Blood. 2021. PMID: 33914079 Free article. No abstract available.

6

Macrophages in multiple myeloma: key roles and therapeutic strategies.

Opperman KS, Vandyke K, Psaltis PJ, Noll JE, Zannettino ACW. Opperman KS, et al. Among authors: vandyke k. Cancer Metastasis Rev. 2021 Mar;40(1):273-284. doi: 10.1007/s10555-020-09943-1. Epub 2021 Jan 6. Cancer Metastasis Rev. 2021. PMID: 33404860 Review.

7

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.

Zeissig MN, Zannettino ACW, Vandyke K. Zeissig MN, et al. Among authors: vandyke k. Cancers (Basel). 2020 Dec 4;12(12):3643. doi: 10.3390/cancers12123643. Cancers (Basel). 2020. PMID: 33291672 Free PMC article. Review.

8

Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo.

Zeissig MN, Hewett DR, Panagopoulos V, Mrozik KM, To LB, Croucher PI, Zannettino ACW, Vandyke K. Zeissig MN, et al. Among authors: vandyke k. Haematologica. 2021 Dec 1;106(12):3176-3187. doi: 10.3324/haematol.2020.253526. Haematologica. 2021. PMID: 33147936 Free PMC article.

9

Characterization of the role of Samsn1 loss in multiple myeloma development.

Friend NL, Hewett DR, Panagopoulos V, Noll JE, Vandyke K, Mrozik KM, Fitter S, Zannettino ACW. Friend NL, et al. Among authors: vandyke k. FASEB Bioadv. 2020 Aug 5;2(9):554-572. doi: 10.1096/fba.2020-00027. eCollection 2020 Sep. FASEB Bioadv. 2020. PMID: 32923989 Free PMC article.

10

Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo.

Clark KC, Hewett DR, Panagopoulos V, Plakhova N, Opperman KS, Bradey AL, Mrozik KM, Vandyke K, Mukherjee S, Davies GCG, Worthley DL, Zannettino ACW. Clark KC, et al. Among authors: vandyke k. Cancers (Basel). 2020 Aug 3;12(8):2149. doi: 10.3390/cancers12082149. Cancers (Basel). 2020. PMID: 32756430 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page